Cardio CRP® testing.
Beyond traditional CHD risk assessment.

First identify. Then intervene.
Get the results that help guide the treatment.

The Cardio CRP® blood test (hs-CRP1) measures vascular inflammation, a strong indicator of future cardiovascular events.1,2 Cardio CRP test results can help you improve risk assessment and recommend appropriate medical or lifestyle intervention.3

The value of Cardio CRP as an additive risk marker

•
Marker of inflammation in the cardiovascular system
•
Independent of LDL-C values3
•
Together, CRP and LDL-C testing predict risk more accurately than LDL-C alone2,3,4

A powerful risk assessment tool

•
FDA-cleared assay for measuring cardiovascular inflammation
•
Detects the small elevations of C-reactive protein that are associated with cardiovascular risk3
•
Can lead to appropriate therapy recommendation in intermediate risk patients (10-20% risk of CHD in the next 10 years)3
•
Same test method 5 used in major studies2,3,4,6

Using Cardio CRP testing to reclassify CHD risk

•
Test patients deemed at Intermediate CHD Risk (according to Framingham/NCEP ATP III Guidelines)3
•
If Cardio CRP results are high (>3-10 mg/L), patients' relative CHD risk approximately doubles3
•
These patients are reclassified as having a High CHD Risk3

Testing is performed fasting or non-fasting. Cardio CRP should be measured twice, two weeks apart, with results averaged. When Cardio CRP level exceeds 10 mg/L, repeat test and examine patient for sources of infection or inflammation.3,5,7

Contact a Quest Diagnostics Sales Representative, learn more about our testing services, and become a client

•
Contact a physician sales representative
•
Contact a hospital sales representative or learn about our complete hospital offerings

References

1 Cardio CRP is also known as high-sensitivity CRP or hs-CRP.
2 Ridker PM, et al. Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular Events. N Engl J Med. 2002;55:445-451.
3 Pearson TA, et al. Markers of Inflammation and Cardiovascular Disease. Application to Clinical and Public Health Practice: A Statement for Healthcare Professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-511.
4 Ridker PM, et al. C-Reactive Protein and Other Markers of Inflammation in the Prediction of Cardiovascular Disease in Women. N Engl J Med. 2000;342:836-843.
5 CardioPhase hsCRP [package insert]. Marburg, Germany: Dade Behring Marburg GmbH; 2004.
6 Yeh ETH, et al. Coming of Age of C-Reactive Protein: Using Inflammation Markers in Cardiology. Circulation. 2003;107:370-371
7 FDA Product Classification Database for Cardiac C-reactive Protein, Antigen, Antiserum, and Control.

< Back to previous page


 E-Prescribing Can Help You Quality For The CMS 2% Incentive Payment Get Started Cardio CRP helps identify patients at risk of first MI even with low-to-moderate risk lipid levels (4). Adding Cardio CRP to standard lipid screening significantly improves risk prediction (1).